SYRE and Spyre Ride New IBD Trends in Biotech Drug Design
Spyre Therapeutics SYRE gives investors a focused view of how inflammatory bowel disease drug development is changing.The company is not built around a single asset. It is pursuing long-acting antibodies, multiple validated immune targets and combination regimens meant to improve disease control wh…